Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2018
Event Date: February 14, 2018 (Agreement effective November 1, 2017)
Context: The Company's wholly-owned subsidiary, Oramed Ltd., entered into a Material Definitive Agreement with Integrium, LLC to serve as a Clinical Research Organization (CRO) for an upcoming clinical trial.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses a specific contractual commitment:
- Contract Value: Up to $7 million total consideration.
- Payment Terms: Payments to be made over the term of the engagement based on the achievement of certain milestones.
Material Changes
The filing reports the entry into a new agreement for clinical trial services. There is no comparative financial data provided in this document to assess changes versus prior periods.
Outlook, Risks, and Unusual Items
Management Commentary and Trial Details:
- Objective: To assess safety and evaluate the efficacy of ORMD-0801 on HbA1c.
- Scope: A three-month dose-ranging clinical trial involving approximately 240 type 2 diabetic patients.
- Regulatory Status: The trial will be conducted under an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.
- Termination: The agreement terminates upon satisfactory performance of all services.
Risks and Contingencies: The filing does not explicitly list risks, though the milestone-based payment structure implies financial outflows are contingent upon trial progress.
Investor Verification Checklist
- Verify the current cash position of Oramed Pharmaceuticals Inc. to assess the ability to fund the up to $7 million milestone payments.
- Confirm the status of the Investigational New Drug (IND) application with the FDA for ORMD-0801.
- Review the specific milestones defined in the agreement with Integrium, LLC that trigger payments.
- Monitor the enrollment progress of the 240-patient dose-ranging trial.